This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Scotland

Prescribing for patients with type 2 diabetes and CV disease: should we be following the Scottish example?

December 2018 Br J Cardiol 2018;25:127–9 doi:10.5837/bjc.2018.030

Prescribing for patients with type 2 diabetes and CV disease: should we be following the Scottish example?

Sean L Zheng

Abstract

Dr Sean L Zheng CVOTs The key studies evaluated sodium-glucose co-transporter 2 (SGLT2) inhibitors – empagliflozin (EMPA-REG OUTCOME)4 and canagliflozin (CANVAS)5 – and glucagon-like peptide 1 (GLP-1) receptor agonists – liraglutide (LEADER)6 and semaglutide (SUSTAIN-6)7 – in patients with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk (table 1). In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) study, the use of empagliflozin resulted in 38% and 35% reductions in cardiovascular death and heart failure hospitalisation, r

| Full text

November 2005 Br J Cardiol 2005;12:409-10

Combating vascular disease in Scotland

Alan G Begg

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now